Clinical Trials
An open label, randomized, laboratory blind, single dose, two period, two treatment, two sequence, two-way crossover, comparative oral bioavailability study of test product Empagliflozin and Metformin Hydrochloride tablets, 12.5/1000 mg of Beximco Pharmaceuticals Limited, Bangladesh with reference product Synjardy 12.5/1000 mg tablet i.e. Empagliflozin and Metformin Hydrochloride tablets, 12.5/1000 mg of Boehringer Ingelheim International GmbH,Germany in healthy adult human subjects under fed conditions.
Principal Investigator: Dr Uttom Kumar BhowmikCRO: M/S. Novas Clinical Research Services Ltd. (NCRSL),
Application Date: 4 Sep, 2023
Bioequivalence clinical study of “test product” tablet TENOBIS 5mg manufactured by Drug International Limited Bangladesh and “Reference product” , tablets ConCOR 5mg manufactured by merck Healthcare KGaA, Germany in healthy Bangladeshi adult Volunteers.
Principal Investigator: Prof Dr Md Saiful IslamCRO: M/S. khwaza Yunus Ali Medical College & Hospital
Application Date: 15 Jul, 2023
A Multi-country, Multi-center, Open-labelled, Randomized Controlled, Extended Phase III Clinical Trial to Evaluate the Immunogenicity and Tolerability of Sabin Strain Inactivated Poliovirus Vaccine Administered with or without Routine Infant Vaccine
Principal Investigator: Dr Wasif Ali KhanCRO: International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b).
Application Date: 24 Apr, 2023
A Multi-country, Multi-center, Open-labelled, Randomized Controlled, Extended Phase III Clinical Trial to Evaluate the Immunogenicity and Tolerability of Sabin Strain Inactivated Poliovirus Vaccine Administered with or without Routine Infant Vaccine
Principal Investigator: Dr Wasif Ali KhanCRO: International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b).
Application Date: 24 Apr, 2023
"Immunogenicity of novel oral poliovirus vaccine type 2 (nOPV2), bivalent oral poliovirus vaccine (bOPV) and inactivated poliovirus vaccine (IPV) administered with different sequential or combination schedules".
Principal Investigator: Dr K ZamanCRO: International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b).
Application Date: 17 Apr, 2023
"A Phase III, Randomized, Observer-blind, Multicenter Study to Evaluate the Efficacy, Immunogenicity and Safety of Seqirus’ Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) Compared to a Non-Influenza Vaccine when Administrated in Healthy Participants aged 6 Months through 47 Months"
Principal Investigator: Dr K zamanCRO: International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b).
Application Date: 17 Apr, 2023
" A Prospective, Single-Blinded, Randomized Control, Comparative Study of Allogeneic Umbilical Cord Derived Mesenchymal Stem Cells With Standard Treatment for Knee Osteoarthritis"
Principal Investigator: Dr Ahmedul KabirCRO: M/S AMZ Hospital ltd
Application Date: 12 Apr, 2023
A Prospective, Randomized, Double blind, Parallel-group, Active controlled study to compare PK, Immunogenicity and Safety of Trastuzumab (Roche) in Healty, Adult ,Human Subjects by single Intravenous Infusion under fasting condition
Principal Investigator: Prof. Dr. Manindranath RoyCRO: M/S ESKEGEN Limited (CRO)
Application Date: 22 Mar, 2023
Bioequivalence Study of Test Product LEVOTHYROXINE SODIUM (100 X 6)mcg TABLET OF NUVISTA PHARMA LTD, BANGLADESH comparing with reference product ELTROXIN (100 X 6) mcg TABLETS containing LEVOTHYROXINE SODIUM 100 mcg of GLAXOSMITHCLINE IN healthy Adult Human Subjects Under Fasting condition" .
Principal Investigator: Dr Uttom Kumar BhowmikCRO: M/S. Novas Clinical Research Services Ltd. (NCRSL),
Application Date: 16 Mar, 2023
"A Co-administration Study of Oral Cholera Vaccine (OCV), Typhoid Conjugate Vaccine (TCV), Measles and Rubella (MR) Vaccines in Bangladesh".
Principal Investigator: Dr Md Taufiqul IslamCRO: International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b).
Application Date: 12 Mar, 2023
Showing 11 to 20 of 65 results
Login with Facebook
Login with Google